{"organizations": [], "uuid": "c0032a28b5ac9b9c0280301e440ac7a409820b4d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/31/globe-newswire-axovant-to-present-at-two-upcoming-investor-conferences.html", "country": "US", "domain_rank": 767, "title": "Axovant to Present at Two Upcoming Investor Conferences", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.433, "site_type": "news", "published": "2018-05-31T15:00:00.000+03:00", "replies_count": 0, "uuid": "c0032a28b5ac9b9c0280301e440ac7a409820b4d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/31/globe-newswire-axovant-to-present-at-two-upcoming-investor-conferences.html", "ord_in_thread": 0, "title": "Axovant to Present at Two Upcoming Investor Conferences", "locations": [], "entities": {"persons": [{"name": "axovant scien", "sentiment": "none"}, {"name": "paul davis", "sentiment": "none"}, {"name": "tricia truehart", "sentiment": "none"}, {"name": "pavan cheruvu", "sentiment": "none"}], "locations": [{"name": "basel", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}], "organizations": [{"name": "jmp securities life science conference", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BASEL, Switzerland, May 31, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 7, 2018 at 9:00 a.m. ET, and at the JMP Securities Life Science Conference on June 21, 2018 at 9:00 a.m. ET.\nA live webcast will be available for each conference in the Investors section of Axovant's website at www.axovant.com . A replay will be available for 30 days following each conference.\nAbout Axovant Sciences\nAxovant is a clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for patients with serious neurologic and neuropsychiatric conditions. Axovant is committed to developing and commercializing a pipeline of product candidates by identifying and developing novel treatments for unmet needs in neurology and psychiatry.\nFor more information, visit www.axovant.com .\nContacts:\nInvestors\nTricia Truehart\n(631) 892-7014\ninvestors@axovant.com\nMedia\nPaul Davis\n(646) 495-5310\nmedia@axovant.com\nSOURCE Axovant Sciences\nSource:Axovant Sciences Ltd.", "external_links": ["https://www.globenewswire.com/Tracker?data=QGQvkc031KLNr6Fowf74sO0Ygsv_eBQfAIZe7nd7u5pocftG88osnEkHORlbCWPQs7ocVz69e7GgCBHlvnBUYFXXrQ8XjfQ-MzGiGAdveHw=", "https://www.globenewswire.com/Tracker?data=eMMbnhPal84NoTCQoItGNU6m1iewEuAln_ZCEtrkLW57A0i9t20uPMAnWNmx8TN8HB89bjhNsjRw78_b6xBI6A==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/7ba56e72-787e-4fc4-93ed-1f9107b52b2a", "https://www.globenewswire.com/Tracker?data=fI-T2_hDrGBXvNCwkPqSfu8l9AQg1ufqKOugUtC7MJaV04YiHL4HrYcwk6CdfjB9U_HjXVnQbnNoLVjmWUoaOQ=="], "published": "2018-05-31T15:00:00.000+03:00", "crawled": "2018-05-31T16:53:34.019+03:00", "highlightTitle": ""}